share_log

Life Seal Vascular Inc. Awarded Prestigious NSF SBIR Grant to Advance Innovative Endovascular Aortic Aneurysm Sac Management Technology

Life Seal Vascular Inc. Awarded Prestigious NSF SBIR Grant to Advance Innovative Endovascular Aortic Aneurysm Sac Management Technology

Life Seal Vascular公司獲得重要的NSF SBIR撥款,推進創新的內血管主動脈動脈瘤囊管理科技。
PR Newswire ·  07/15 11:03

More than $274,000 in NSF funding to develop breakthrough aneurysm sac management technology

美國國家科學基金會撥款超過27.4萬美元,用於開發突破性的動脈瘤囊管理技術

COSTA MESA, Calif., July 15, 2024 /PRNewswire/ -- Life Seal Vascular Inc. (), a pioneering company dedicated to revolutionizing endovascular treatment, is thrilled to announce that it has been awarded the highly competitive National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant. This funding will accelerate the development of Life Seal Vascular's cutting-edge technology to improve patient outcomes and advance the field of endovascular aortic repair (EVAR).

加利福尼亞州科斯塔梅薩,2024年7月15日 /PRNewswire/ — 致力於革新血管內治療的開創性公司Life Seal Vascular Inc. () 很高興地宣佈,它已獲得競爭激烈的國家科學基金會(NSF)小型企業創新研究(SBIR)資助。這筆資金將加速Life Seal Vascular尖端技術的開發,以改善患者預後並推進血管內主動脈修復(EVAR)領域。

Life Seal Concept
生命印章概念

"We are honored to receive this prestigious SBIR grant from the NSF. This funding is a testament to the innovative potential of our technology and our commitment to advancing EVAR care," said Bob Mitchell, Executive Chairman of the Board at Life Seal Vascular Inc. "With this support, we are well-positioned to advance the development of our breakthrough aneurysm sealing solutions and make a significant impact on the lives of EVAR patients worldwide."

“我們很榮幸獲得美國國家科學基金會的這筆久負盛名的SBIR資助。這筆資金證明了我們技術的創新潛力以及我們對推進EVAR護理的承諾,” Life Seal Vascular Inc董事會執行主席鮑勃·米切爾說,“有了這種支持,我們完全有能力推進突破性動脈瘤密封解決方案的開發,並對全球EVAR患者的生活產生重大影響。”

The NSF SBIR grant will enable Life Seal Vascular to further develop its proprietary aneurysmal sac sealing technology. Designed as an adjunctive therapy to native endografts, Life Seal Vascular's groundbreaking approach seals the entire aneurysmal sac potentially eliminating endoleaks, reducing reintervention rates and improving clinical outcomes for EVAR patients.

NSF SBIR撥款將使Life Seal Vascular能夠進一步開發其專有的動脈瘤囊密封技術。Life Seal Vascular的開創性方法是天然內移植的輔助療法,其開創性的方法可以密封整個動脈瘤囊,有可能消除內滲漏,降低再幹預率,改善EVAR患者的臨床結果。

Dr. Michel Reijnen, a renowned vascular surgeon, commented on the significance of Life Seal Vascular's technology, stating, "The advancements being made by Life Seal Vascular are truly remarkable. Their innovative solutions have the potential to revolutionize EVAR, offering patients safer and more effective treatment options. I am excited to see the positive impact this technology will have on the field and on patient care."

著名血管外科醫生米歇爾·雷傑寧博士評論了Life Seal Vascular的技術的重要性,他說:“Life Seal Vascular取得的進步確實非常了不起。他們的創新解決方案有可能徹底改變EVAR,爲患者提供更安全、更有效的治療選擇。我很高興看到這項技術將對現場和患者護理產生積極影響。”

The NSF SBIR program is a highly competitive initiative that supports scientific excellence and technological innovation through the investment of federal research funds. Life Seal Vascular's selection for this grant underscores the company's dedication to advancing medical technology and its potential to deliver transformative healthcare solutions.

NSF SBIR計劃是一項競爭激烈的計劃,通過聯邦研究資金的投資來支持卓越的科學和技術創新。Life Seal Vascular選擇這筆撥款凸顯了該公司致力於推進醫療技術的發展及其提供變革性醫療解決方案的潛力。

This grant is supported by the U.S. National Science Foundation under award number 2407378.

該補助金由美國國家科學基金會支持,獎勵編號爲2407378。

About Life Seal Vascular, Inc.
Life Seal Vascular Inc. specializes in innovative sealing technologies for endovascular repair of aortic aneurysms. Their proprietary solutions has the potential to eliminate endoleaks, the main cause of reinterventions in Endovascular Aneurysm Repair (EVAR). By completely sealing the aneurysm, Life Seal Vascular's devices ensure predictable deployment and do not interfere with imaging, thereby enhancing the effectiveness and safety of endovascular repair procedures.

關於 Life Seal Vascular, Inc
Life Seal Vascular Inc. 專門研究用於主動脈瘤血管內修復的創新密封技術。他們的專有解決方案有可能消除內滲漏,這是血管內動脈瘤修復(EVAR)再幹預的主要原因。通過完全密封動脈瘤,Life Seal Vascular的設備可確保可預測的部署且不會干擾成像,從而提高血管內修復手術的有效性和安全性。

For more information about Life Seal Vascular Inc. and its groundbreaking technology, please visit []().

有關 Life Seal Vascular Inc. 及其開創性技術的更多信息,請訪問 [] ()。

About U.S. National Science Foundation Small Business Program
America's Seed Fund powered by the U.S. National Science Foundation Small Business programs focuses on transforming scientific and engineering discoveries into products and services with commercial and societal impact. The deep technologies that are funded show promise, but their success hasn't yet been validated. And, each year, the NSF awards $200+ million in research and development (R&D) funding to about 400 startups across the United States. America's Seed Fund is a program within the National Science Foundation and housed within the Directorate for Technology, Innovation and Partnerships.

關於美國國家科學基金會小企業計劃
美國種子基金由美國國家科學基金會小型企業項目提供支持,專注於將科學和工程發現轉化爲具有商業和社會影響的產品和服務。獲得資助的深度技術顯示出希望,但其成功尚未得到證實。而且,NSF每年向美國約400家初創公司提供超過2億美元的研發(R&D)資金。美國種子基金是美國國家科學基金會下屬的一項計劃,設在技術、創新和夥伴關係局內。

Media Contact:
Bob Mitchell
Executive Chairman of the Board

媒體聯繫人:
鮑勃米切爾
董事會執行主席

Life Seal Vascular Inc.
Hannah Friend
602-618-3377
[email protected]

Life Seal 血管公司
漢娜·弗裏德
602-618-3377
[電子郵件保護]

SOURCE Life Seal Vascular, Inc.

來源 Life Seal Vascular, Inc

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論